Regulatory Roundup - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Regulatory Roundup
Compounding, tracking legislation moves forward

Pharmaceutical Technology
Volume 37, Issue 7, pp. 26

Overseeing China
Concerns about recent bird flu outbreaks and public health issues in China are drawing scrutiny from Congress and interest in bolstering FDA oversight of soaring food and drug imports from that country. Shipments of FDA-regulated products from China increased from 1.3 million entry lines in 2007 to 4.5 million in 2012, reported Steven Solomon, FDA associate director for global operations and policy, at a May hearing by the Congressional-Executive Commission on China. Solomon noted that FDA now has 74 active import alerts for Chinese food and drug products, which allow detention or refusal of entry into the US, and that the agency is collaborating more with the Chinese FDA (CFDA) to address concerns. FDA staffers meet regularly (by video conference) with Chinese counterparts to discuss economically motivated adulteration of products and have worked jointly to shutdown websites illegally selling unapproved drugs. CFDA has provided FDA's China office with a list of domestic pharmaceutical firms that failed to comply with GMPs, enabling FDA to target 61 violative firms shipping products to the US.

ARV supply chain
The President's Emergency Plan for AIDS Relief (PEPFAR) marked its 10th anniversary in May 2013, amid kudos for success in providing antiretroviral therapy to millions of stricken individuals in Africa and other nations, as well as calls for more effective and efficient treatment and care programs. So far PEPFAR has provided $1.2 billion in ARV drugs to some 5 million people, promoting the use of combination therapy and transforming the deadly disease into a manageable epidemic in some places. An April 2013 report from the Government Accountability Office notes the need for better controls and recordkeeping to ensure that ARV supply chains are secure and establish appropriate inventory controls and records to avoid shortages, waste and loss of inventory. The aim is to expand the program to serve 23 million eligible people, and further improvements in drug supply chains are "critical," the study concludes (2).

Shortages in TB treatments
Efforts to control and treat tuberculosis have been hampered by a shortage of first-line treatment isoniazid (INH), according to reports from the Centers for Disease Control and Prevention (CDC). Manufacturers have had problems obtaining active ingredient supplies, prompting production delays. Shortages in all TB drugs are even more severe in India and other regions, fueling a spread of multi-drug resistant TB strains as patients are forced to stop taking medicines. Manufacturers Sandoz and Teva have moved to ramp up production in response to a temporary shutdown at VersaPharm. A lack of clear procurement projections by government health programs, as well as low prices for these widely used drugs, have discouraged additional manufacturers to move into the TB drug market.

1. Avalere Health, An Analysis of Access to Anticonvulsants in Medicare Part D and Commercial Health Insurance PlanS, June 2013,

2. GAO, President's Emergency Plan For AIDS Relief: Drug Supply Chains Are Stronger, but More Steps Are Needed to Reduce Risks, GAO-13-483, Apr. 26, 2013,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here